Anti-PD-1/L1 Lead-In before MAPK Inhibitor Combination Maximizes Antitumor Immunity and Efficacy

Researchers compared the efficacies of sequential and/or combinatorial regimens in subcutaneous murine models of melanoma driven by BrafV600, Nras, or Nf1 mutations as well as colorectal and pancreatic carcinoma driven by KrasG12C.